Medical Center Vereya EOOD
- Address
- lock Available on a paid plan
Eye Diseases (C11)
The Medical Center Vereya EOOD focuses on eye diseases, conducting trials aimed at improving vision and reducing disease‑related complications. Current research evaluates new treatments for conditions such as Diabetic Macular Edema, neovascular age‑related macular degeneration, and thyroid eye disease. The goal is to test safety and effectiveness of innovative therapies, potentially lowering treatment burden and preserving visual acuity.
- Evaluation of a novel eye‑drop formulation for Diabetic Macular Edema
- Assessment of a subcutaneous antibody for thyroid eye disease
- Comparison of gene‑therapy versus anti‑VEGF injections for neovascular AMD
With three ongoing studies and two principal investigators, the site in Stara Zagora, Bulgaria, is contributing valuable data to the field of ophthalmology.
Ocular Physiological Phenomena (G14)
Research at this center also addresses ocular physiological phenomena, exploring how the eye responds to therapeutic interventions. Trials investigate the impact of treatments on retinal fluid dynamics, inflammatory processes, and proptosis reduction, providing insight into disease mechanisms and patient outcomes.
- Study of retinal fluid resolution in Diabetic Macular Edema
- Investigation of proptosis response in thyroid eye disease
- Long‑term visual acuity preservation in neovascular AMD
By integrating physiological assessments with clinical endpoints, the Medical Center Vereya EOOD enhances understanding of eye health and supports the development of more effective ocular therapies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Center Vereya EOOD
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects with Neovascular Age-Related Macular Degeneration (nAMD) | AbbVie Deutschland GmbH & Co. KG | Phase I | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 1 | Unknown | — | — |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.